医药地区主管-苏州

Chinese national high-tech pharmaceutical company founded on 7 September 2005 in the Miaoshan pharmaceutical park of the East Lake development zone in Wuhan, Hubei, occupying more than 360 mu with total project investment of 536 million yuan. Integrates manufacturing, research and sales through five wholly owned subsidiaries comprising two research centres, two production bases and a marketing centre. Its flagship product family is ornithine aspartate under the Ruigan brand, whose granules were listed in China's 2020 national reimbursement catalogue, alongside fasudil mesylate for injection and sofalcone dry suspension. Has completed innovation programmes to international standards in liver disease, cardiovascular and cerebrovascular disease, digestive disease, fungal infection and respiratory medicine and undertaken around forty national projects including major new drug creation programmes.